Showing results (1311-1320 of 1,518) with videos related to

Sort By:
Pageof 152
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21Andrea Bezjak, Dongsheng Tu, Lesley Seymour, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancerE F Smit, M A Socinski, B P Mullaney, et al.
Journal of Pediatric Surgery|June 7, 2021
One-year impact of a bowel management program in treating fecal incontinence in patients with anorectal malformationsRichard J Wood, Alejandra Vilanova-Sanchez, Yousef El-Gohary, et al.
Neuron|March 25, 2014
Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stallingLong Cheng, Jigar Desai, Carlos J Miranda, et al.
Cancer Medicine|January 28, 2023
Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patientsJulia Walter, Diego Kauffmann-Guerrero, Thomas Muley, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|July 9, 2021
Contact Allergy in Canada Versus United States: Analysis of the North American Contact Dermatitis Group Data 2005-2016Amber Reck Atwater, Jordan Maxwell Ward, Beiyu Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso TrialFederica Grosso, Nicola Steele, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCMark A Socinski, Makoto Nishio, Robert M Jotte, et al.
Pageof 152